CD37

CD37

a type III transmembrane protein present on mature B cells, some T cells, and monocytes that may play a role in ion transport; expressed on B-cell lymphomas, B-cell chronic lymphocytic leukemia, and hairy cell leukemia.
References in periodicals archive ?
2/8H5) from LifeSpan BioSciences (Seattle, WA, USA); Annexin V (AF399), CD4 (34930), CD8a (37006), CD19 (4G7-2E3), CD37 (424925), CD45 (2D1), CD80 (37711), CD82 (423524), CD83 (HB15e), MIC A/B (159207), TNF RI, and TNF RII from R&D Systems (Minneapolis, MN, USA); TLR3 (3.
Immunological markers Functional Regulatory Adhesion Lineage-specific and others HLA-DR CTLA-4 CD11a CD3 HLA-ABC PD-L1 ICAM-1 CD4 CD28 CD8 CD80 CD14 CD49d CD16 TLR3 CD19 Fas-L CD37 MIC A/B CD41 TNF RI CD42a TNF RII CD45 CD56 CD83 Vesicle-related markers Functional Tetraspanins Others HLA-DR CD9 TSG101 HLA-ABC CD63 Alix CD28 CD81 Flotillin-1 CD80 CD82 Annexin V CD49d TLR3 Fas-L MIC A/B TNF RI TNF RII HLA: human leukocyte antigen; TLR: Toll-like receptor; TNF: tumor necrosis factor: RI: receptor I, RII: receptor II; MIC A-B: major 1; TSG101: tumor susceptibility gene 101.
Trubion retains the right to develop and commercialize, on its own or with others, product candidates directed to all targets not included within the agreement, including CD37.
Gene expression of T-cell markers such as CD3 a subunit of the T-cell receptor, was decreased in spleen, whereas in blood, HCB decreased gene expression for CD3 and CD37, the latter being a B-cell marker.
NYSE: EBS) today announced that the European Commission granted orphan medicinal product designation to Emergent's humanized single chain monoclonal antibody against CD37, also called TRU-016, for the treatment of chronic lymphocytic leukemia (CLL).
ImmunoGen created IMGN529 for the treatment of B-cell malignancies that express its CD37 target.
ORAL PRESENTATION: Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals Publication #622 Monday, December 12, 2011, 3:30 PM
Among the data reported were that CD37 expression is comparable to that of CD20 on key NHL subtypes and CLL; that in preclinical testing the antibody component of IMGN529 demonstrates anticancer activity comparable to or greater than that of Rituxan[R] (rituximab); and that the complete IMGN529 TAP compound - antibody with attached DM1 cell-killing agent - demonstrates significantly greater anticancer activity than rituximab in preclinical models.
CD37 met these criteria; however, it was known to be difficult to develop humanized antibodies to this target that also have potent anticancer activity.
The prevalence of CD37 is comparable to that of CD20 on key B-cell malignancy subtypes such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma (BL), and mantle cell lymphoma (MCL).
Of the therapeutics currently in development, targeting CD37 with TRU-016 appears to be among the most promising.
a clinical-stage CD37 targeted SMIP candidate (TRU-016) for the treatment of Chronic Lymphocytic Leukemia (Phase 1/2), Non-Hodgkin's Lymphoma (Preclinical/Phase 1) in partnership with Abbott; and